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Abstract
Background: Although the incidence of dengue across Africa is high, severe dengue is reported infrequently. We
describe the clinical features and the outcome of dengue according to raceduring an outbreak in Dar es Salaam,
Tanzania that occurred in both native and expatriate populations.
Methods: Adults with confirmed dengue (NS1 and/or IgM on rapid diagnostic test and/or PCR positive) were
included between December 2013 and July 2014 in outpatient clinics. Seven-day outcome was assessed by a visit
or a call. Association between black race and clinical presentation, including warning signs, was assessed by logistic
regression adjusted for age, malaria coinfection, secondary dengue and duration of symptoms at inclusion. The
independent association between demographic and comorbidities characteristics of the patients and severe
dengue was evaluated by multivariate logistic regression that included potential confounders.
Results: After exclusion of 3 patients of mixed race, 431 patients with dengue (serotype 2, genotype
Cosmopolitan) were included: 241 of black and 190 of non-black race. Black patients were younger (median
age 30 versus 41 years; p < 0.001) and attended care after a slightly longer duration of symptoms (median of
2.9 versus 2.7 days; p = 0.01). Malaria coinfection was not significantly different between black (5%) and non-black
(1.6%) patients (p = 0.06). The same proportion of patients in both group had secondary dengue (13 and 14%; p = 0.78).
Among warning signs, only mucosal bleed was associated with race, black race being protective (adjusted OR 0.44;
95% CI 0.21–0.92). Overall, 20 patients (4.7%) presented with severe dengue. Non-black race (adjusted OR 3.9;
95% CI 1.3–12) and previously known diabetes (adjusted OR 43; 95% CI 5.2–361) were independently
associated with severe dengue.
Conclusions: Although all patients were infected with the same dengue virus genotype, black race was
independently protective against a severe course of dengue, suggesting the presence of protective genetic or
environmental host factors among people of African ancestry. The milder clinical presentation of dengue in
black patients might partly explain why dengue outbreaks are under-reported in Africa and often mistaken for
malaria. These results highlight the need to introduce point-of-care tests, beside the one for malaria, to detect
outbreaks and orientate diagnosis.
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Background
Uncontrolled urbanization, human mobility and changes
in ecosystems have led to a 30-fold increase of dengue
incidence in the last 50 years with geographic expansion
to new countries [1]. The America, South-East Asia and
western Pacific regions are the most affected [2]. Al-
though dengue is known to circulate in Africa since the
nineteenth century, and despite that up to 30 African
countries have identified cases, the clinical impact and
epidemiology of dengue in this part of the world remains
poorly characterized [3]. Current estimates suggest that
sub-Saharan Africa carries 16% of the annual worldwide
burden, but dengue is often not recognized, and hence
under-reported because of its non-specific clinical pres-
entation leading to presumptive diagnosis of malaria.
Lack of awareness among clinicians, limited diagnostic
capacities and weak surveillance systems may also con-
tribute to underestimation of dengue. A limited number
of dengue-infected patients will progress to severe dis-
ease which has more specific characteristics and is easier
to identify. Although the incidence of dengue across Af-
rica is high, severe dengue has been reported infre-
quently [3]. To our knowledge, no study has been
conducted in Africa evaluating the association between
race and dengue presentation and outcome.
Since 2010, dengue outbreaks have been identified in
Tanzania [4–6]. We describe the clinical features and
outcome of dengue during the first documented out-
break in Dar es Salaam that occurred in 2013–14 in both
native and expatriate populations of different races.
Methods
Study design and setting
Patients were recruited between December 2013 and
July 2014 in four public clinics and one private clinic in
Kinondoni, the most populated (1.8 million inhabitants)
District of Dar es Salaam, the largest city and economic
center of Tanzania.
Study participants
Patients recruited in public and private clinics
A prospective cohort study to document the etiologies
of fever was performed between December 2013 and
July 2014 at the emergency departments of Mwananya-
mala Regional Hospital and connected health care facil-
ities (Sinza Hospital, Magomeni Health Centre, Tandale
Health Centre). All consecutive adult (age ≥ 18 years)
patients presenting with fever (tympanic temperature ≥
38.0 °C) lasting for 7 days or less at the emergency de-
partments were prospectively screened for inclusion in
the study. Simultaneously, consecutive adult patients
who presented for medical care in the IST private clinic
were screened for dengue in case of clinical suspicion
with symptoms lasting for 7 days or less by the medical
doctor in charge. Patients diagnosed with dengue (defin-
ition below) were included in the present study. The
clinical outcome was assessed by a visit or a call 7 days
after inclusion in the study.
Dengue
Dengue was defined as a positive NS1 antigen or IgM
detection with rapid diagnostic test (SD BIOLINE
Dengue Duo®) and/or a positive PCR (Fast-track DIAG-
NOSTICS tropical fever core®).
Secondary dengue infection was defined as evidenced
of previous dengue infection as determined by anti-
dengue virus IgG detection with rapid diagnostic test
during the acute phase (≤5 days of symptoms) of the dis-
ease as previously defined [7, 8].
Race
Patients were categorized into two groups according to
their self-defined race. Those with African ancestry were
in the group of patients with black race (black patients
from Tanzania and other sub-Saharan African countries)
and those without African ancestry were in the group
with non-black race (non-black patients from Europe,
US, Australia, Asia, Middle East, South Africa).
Study procedures
Data collection
Demographic characteristics, race, comorbidities and
symptoms and signs were collected at inclusion using
electronic or paper case report forms. Blood pressure
was measured with an automated device (Omron® M6).
The socio-economic status of black patients was catego-
rized based on indicators of education and wealth.
Non-black patients were all expatriates and were consid-
ered as having a high socio-economic status.
GPS localization of patients’ home was recorded.
Data were entered directly into an open data kit in a
personal digital assistant with real-time error, range
and consistency checks [9].
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Laboratory investigations
Rapid diagnostic tests for dengue (SD BIOLINE Dengue
Duo®) and malaria (ICT Malaria P.f.®) were systematically
performed in patients on site on the day of the inter-
view. Participants enrolled in the public clinics were sys-
tematically screened for HIV in accordance with the
national algorithm (rapid test, Alere Determine™ HIV-1/
2, and for confirmation, a second rapid test, Trinity Bio-
tech Uni-gold™ Recombigen® HIV-1/2). Real-time multi-
plex PCR (Fast-track DIAGNOSTICS tropical fever
core®) targeting dengue virus and Plasmodium was per-
formed in all patients recruited in the public hospitals.
Real-time multiplex PCR (Fast-track DIAGNOSTICS
Dengue differentiation®) for the detection of dengue
virus type 1, 2, 3 and 4 was done in all patients with a
positive rapid diagnostic test for dengue in the public
and private clinics. RT-PCR analyses were performed at
the virology laboratory of the University Hospital of
Geneva in Switzerland. Genotyping of dengue virus was
performed at the arbovirus and imported viral disease la-
boratory, National Centre of Microbiology, Madrid,
Spain, in a subgroup of randomly selected cases; 4 pa-
tients per week (2 in the public and 2 in the private
clinic) during the dengue outbreak. A partial and
complete envelope gene sequence was obtained using
previously described protocols for amplification and se-
quencing for dengue serotype 2 (DENV-2) [10].
Complete blood count was performed (Horiba Medical
ABX Pentra 80 hematology analyzer) at inclusion. Low
platelet count was defined as < 100 × 109/L, high
hematocrit level as > 45% and low leukocyte count as <
3.5 × 109/L.
Dengue warning signs and severe dengue
Dengue warning signs and severe dengue were defined
according to WHO recommendations [11]. Warning
signs included abdominal pain, persistent vomiting
(vomiting during two or more consecutive days), clinical
fluid accumulation and mucosal bleed. Three of the
seven warning signs, namely liver enlargement, lethargy
and increase in hematocrit concurrent with rapid de-
crease in platelet count were not included as these pa-
rameters were not routinely collected. Severe dengue
was defined as the presence of at least one of the four
following criteria: 1) Circulatory compromise or shock
defined as narrow pulse pressure ≤ 20 mmHg or low sys-
tolic blood pressure < 90 mmHg, 2) Severe hemorrhage
defined as gastrointestinal tract bleeding such as hema-
temesis, melena or rectorrhagia or menorrhagia, 3) al-
tered mentation defined as a Glasgow coma score of 14
or lower, 4) death within 7 days of follow-up. Severe
organ impairment was not a criterion of severe dengue
as liver and renal functions were not systematically mea-
sured. The clinical outcome and the occurrence of
warning signs were recorded at inclusion and by a
follow-up visit or call at day seven with the exception of
blood count values and blood pressure which were mea-
sured at inclusion only.
Data analysis
Demographic, comorbidities, clinical and laboratory
characteristics as well as outcome of dengue patients
of black race were compared to those of non-black
raceusing Wilcoxon-Mann-Whitney and chi-square
tests. In a sub-group analysis, black patients included
in the public clinics were compared to those included
in the private clinic to account for potential inter-
observer variation.
Each warning sign as well as hematocrit and platelets
count were evaluated for their association with black
race using univariate logistic regression and multivariate
logistic regression including potential confounders, i.e.
age, malaria coinfection, secondary dengue and duration
of symptoms at inclusion.
The independent association between demographic
and comorbidities characteristics of the patients and the
occurrence of severe dengue was evaluated by multivari-
ate logistic regression that included potential
confounders.
Statistical analyses were performed using Stata soft-
ware (StataCorp, College Station, TX, USA, version 12)
and GraphPad Prism 6. Google Earth was used for
Fig. 2.
Results
Characteristics of patients of black and non-black race
A total of 431 adult patients with laboratory-
confirmed dengue were enrolled in the study. 185
black patients native of Tanzania were enrolled in
the public hospitals and 246 patients with different
races in the private clinic. Three patients were ex-
cluded because of mixed-race leaving 428 patients
for analysis (Fig. 1).
Of the 428 dengue patients, 240 were black (185 native
Tanzanians recruited in the public clinics; 46 native Tan-
zanians and 9 from other African countries recruited in
the private clinic) and 188 non-black (121 Europeans or
Americans, 3 Australians, 39 Asians, 8 from the Middle
East and 17 white South Africans recruited in the private
clinic). Patients lived in different regions of Dar es Sa-
laam (Fig. 2).
All were infected with same strain of DENV-2 (suc-
cessful genotyping in 53 out of 87 samples), that be-
long to Cosmopolitan genotype and was closely
related to strains of DENV-2 isolated in Asia in
2013–2014. Strains from the Tanzanian outbreak
formed a separate group with Asian strains recently
detected in China and Indonesia.
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Characteristics of the patients are described in
Table 1. Black patients were younger (median age of
30 versus 41 years; p < 0.001) and presented to the
clinic after a slightly longer duration of symptoms
(median of 2.9 versus 2.7 days; p = 0.01). Seventy-four
percent of black patients and none of the non-black
patients had a low socioeconomic status. The preva-
lence of malaria co-infection was not significantly
higher in patients of black (5%) than non-black (1.6%)
race (p = 0.06). The same proportion of patients in
both groups had secondary dengue (13 and 14%, p =
0.78). Regarding the clinical presentation of dengue,
patients of black race had a higher prevalence of
headache (92 and 82%, p = 0.003) and myalgia/arthral-
gia (76% versus 55%, p < 0.001) and a lower preva-
lence of rash (4.2 and 47%, p < 0.001). Black patients
had a lower prevalence of low blood pressure (0.8%
versus 4.8%; p = 0.003), but the same proportion of
patients in both groups had narrow pulse pressure
(0.8% versus 2.7%; p = 0.14). Of note, blood pressure
was not measured and assumed to be normal in 129
patients (30%); 36 black patients (15%) and 93
non-black patients (49%).
Regarding warning signs, the prevalence of mucosal
bleed was lower in black patients (5.8% versus 13%; p =
0.01). The prevalence of severe dengue was lower in pa-
tients of black race (2.5%) compared to those of
non-black (7.5%) race (p = 0.02).
Compared to black patients included in the private
clinic, black patients included in the public clinics
were younger (median age of 27 versus 39 years; p <
0.001; Additional file 1: Table S1). Regarding the clin-
ical presentation of dengue, black patients included in
the public clinic had a higher prevalence of headache
(96% versus77%; p < 0.001) and myalgia/arthralgia
(80% versus 62%; p = 0.006) and a lower prevalence of
Fig. 1 Flow chart of study participants
Fig. 2 Geolocalisation of dengue patients. a Geolocalisation of patients of black race. b Geolocalisation of patients of non-black race
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rash (0% versus 18%; p < 0.001) compared to black pa-
tients included in the private clinic. However, the
same proportion of patients in both groups had
hypotension (0.5% versus 0%; p = 0.59) and narrow
blood pressure (1.1% versus 0%; p = 0.44). The
proportion of patients with mucosal bleeding (6.0%
and 5.5%; p = 0.89) and with severe dengue (3.2% and
0%; p = 0.18) was not different between black patients
included in the public hospitals and those included in
the private clinic.
Table 1 Baseline characteristics and day-7 outcome of study participants according to race
All Black patients Non-black patients P value
N = 428 N = 240 N = 188
N(%) or Median (IQR)
Age, years 35 (27–45) 30 (23–40) 41 (34–49) < 0.001
Male sex 227 (53) 135 (56) 92 (49) 0.13
Low socioeconomic status 178 (42) 178 (74) 0 (0) < 0.001
Malaria coinfection 15 (3.5) 12 (5.0) 3 (1.6) 0.06
Pregnancy 8 (1.9) 5 (2.1) 3 (1.6) 0.71
HIV a 11 (2.6) 11 (4.6) 0 (0) NA
History of diabetes 6 (1.4) 3 (1.3) 3 (1.6) 0.76
Secondary dengue 57 (13.3) 31 (13) 26 (14) 0.78
Symptoms and signs at inclusion
Duration of symptoms, days; Mean (SD) 2.8 (1.4) 2.9 (1.3) 2.7 (1.6) 0.01
Headache 374 (87) 220 (92) 154 (82) 0.003
Rash 98 (23) 10 (4.2) 88 (47) < 0.001
Myalgia/Arthralgia 286 (67) 182 (76) 104 (55) < 0.001
Vomiting 87 (20) 47 (20) 40 (21) 0.67
Systolic blood pressure < 90mmh b 10 (2.3) 1 (0.4) 9 (4.8) 0.003
Pulse pressure≤ 20 mmHg b 7 (1.6) 2 (0.8) 5 (2.7) 0.14
Altered mental status; Glasgow Coma Score < 15 2 (0.5) 2 (0.8) 0 (0) 0.21
Warning signs at inclusion and within 7 days of follow-up 129 (30) 67 (28) 62 (33) 0.26
Abdominal pain 66 (15.4) 40 (17) 26 (14) 0.42
Persistent vomiting 40 (9.4) 23 (9.6) 17 (9.0) 0.85
Clinical fluid accumulation 4 (0.9) 2 (0.8) 2 (1.1) 0.81
Mucosal bleed 42 (9.7) 14 (5.8) 24 (13) 0.01
Laboratory parameters at inclusion c
Hemoglobin, mg/l 14 (13–15) 14 (13–15) 14 (12–15) 0.48
Hematocrit, % 42 (39–46) 42 (38–46) 43 (40–46) 0.005
Hematocrit > 45% 120 (28) 54 (23) 66 (35) 0.004
Leukocytes, ×109/L 4.5 (3.1–6.0) 4.6 (3.1–6.2) 4.2 (3.0–5.6) 0.16
Leukocytes < 3.5x109G/L 143 (33) 76 (32) 67 (36) 0.39
Platelets, ×109/L 150 (115–189) 147 (106–195) 11 (122–178) 0.82
Platelets < 100 × 109/L 70 (16) 48 (20) 22 (12) 0.02
Clinical outcome at day 7
Severe dengue d 20 (4.7) 6 (2.5) 14 (7.5) 0.02
Death 2 (0.5) 2 (0.8) 0 (0) 0.21
Admission 39 (9.1) 21 (8.8) 18 (9.6) 0.77
Intravenous fluid 55 (13) 18 (7.5) 37 (20) < 0.001
aHIV screening was systematically performed in the public clinics only; b Missing blood pressure measurement in 129 patients (in 36 black and in 93 non-black
patients); blood pressure was assumed to be within the normal range if missing; c Blood count values missing in 18 patients; d patients who died are included
among patients with severe dengue
Abbreviations: NA Not applicable
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Association between each warning sign as well as blood
count parameters and black race
Except for mucosal bleed, there was no association be-
tween warning signs and race. Black race was protective
against mucosal bleed (adjusted odds ratio (OR) 0.44;
95% confidence interval (CI) 0.21–0.92) even after ad-
justment for potential confounders (age, malaria
co-infection, secondary dengue and duration of symp-
toms at inclusion; Table 2). Regarding blood count pa-
rameters, high hematocrit was associated with non-black
race (adjusted OR 2.0; 95% CI 1.3–3.2) even after adjust-
ment for hemoglobin value (adjusted OR 2.1; 95% CI
1.3–3.3), while the presence of a low platelets count was
associated with black race (adjusted OR 1.8; 95% CI 1.0–
3.3).
Factors associated with severe dengue
Overall, 20 patients out of 428 (4.7%) presented with se-
vere dengue and among them, two died. The criteria
classifying them as severe dengue was low systolic blood
pressure in 7, narrow pulse pressure in 5, both low sys-
tolic pressure and narrow pulse pressure in 2, severe
hemorrhage in 3, cardiac failure in 1. The two patients
who died presented with altered mental status and one
also presented with severe hemorrhage and low systolic
blood..
The socio-demographic characteristics (age, sex and
socioeconomic status) of patients who presented with
severe dengue were similar to those who had a milder
course of disease. Secondary dengue was not a factor as-
sociated with severe dengue (adjusted OR 1.5; 95% CI
0.4–5.4) (Table 3). Non-black race (adjusted OR 3.9; 95%
CI 1.3–12) and known diabetes (adjusted OR 43; 95% CI
5.2–361) were independently associated with severe den-
gue even after adjustment for potential confounders.
Discussion
Although all patients were infected with the same den-
gue virus genotype, black race was independently pro-
tective against a severe course of dengue. These results
support the hypothesis of protective genetic or environ-
mental (such as protection after previous exposure to
the same dengue strain and cross-protection after expos-
ure to other arboviruses or vaccine) host factors among
people of African ancestry.
Our results are in line with previous epidemiologic
data showing the absence of severe dengue in Haiti be-
tween 1994 and 1996 despite high transmission and by
data from the 1981 and 1997 dengue epidemics in Cuba
showing a lower rate of hemorrhagic manifestations and
hospitalization among subpopulations of African ances-
try [12–16]. The Cuban studies also showed that
non-black individuals were disproportionately suscep-
tible to dengue [17]. De La Sierra et al. reported a
stronger and cross-reactive dengue virus-specific mem-
ory CD4+ T cell proliferation and interferon-gamma re-
lease in white people compared to black people in 80
Cuban donors previously infected with dengue [18].
Blanton et al. also reported an association between Afri-
can ancestry and a reduced risk of severe dengue in
Brazil [3, 19]. In addition, a genetic study from Brazil
identified a strong association between a polymorphism
in JAK1 and severe dengue and showed a different dis-
tribution of mutations by race consistent with the epide-
miologic data [20]. In Colombia, an epidemiological
study also showed that the Afro-Colombians population
had a significantly lower risk of getting dengue and its
complications, compared with the non-Afro-Colombians
population [21].
In our study, several factors may explain a lower sus-
ceptibility to severe disease among the population of
black race. Differences in patients’ characteristics, health
facility attended and environmental exposure have been
identified between black and non-black patients and
might have led to some bias in the link between dengue
severity and race.
Different patients’ characteristics such as age and
socio-economic status were related to race. Black pa-
tients were younger and most of them had a low
socio-economic status. Older age has been associated
with severe dengue in previous reports [11, 22, 23].
However, our analyses were adjusted for age and age was
not a factor associated with a severe course of dengue.
Low et al. reported that older age was associated with a
lower prevalence of myalgia, arthralgia, headache and
mucosal bleeding [24]. Age difference between patients
of black and non-black race could explain part of the
differences observed in the clinical presentation of den-
gue. Low socio-economic status has also been linked to
an increased risk of severe dengue [25]. Blanton et al.
addressed both race and socioeconomic factors in a case
control study in Brazil and concluded that both ancestry
and income are factors associated with severe dengue
[19]. In our study, socio-economic status could be a po-
tential confounder as income and race are closely inter-
related in this Tanzanian setting. However, it cannot
explain the reduced dengue severity among black
patients as they had a lower socio-economic status
compared to non-black patients. Hemoglobin and
hematocrit values might also be linked to race as they
are known to be lower in persons of African race [26].
As we do not have values outside of the disease episode,
we cannot establish with certainty a link of causality be-
tween higher hematocrit value in non-black patients and
dengue severity.
The patients were included by two different study
teams which might have led to differences in patients’
evaluation. Patients included in the private clinic were
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Table 2 Association between each warning sign as well as laboratory parameters and black race
OR or coefficient (95% CI) P
value
OR or coefficient (95% CI) P
valueUnadjusted Adjusted a
Warning signs at inclusion and within 7 days of follow-up 0.79 (0.52–1.2) 0.26 0.77 (0.49–1.2) 0.26
Abdominal pain 1.2 (0.7–2.1) 0.42 1.2 (0.67–2.1) 0.56
Persistent vomiting 1.1 (0.55–2.1) 1.0 0.95 (0.46–2.0) 0.90
Clinical fluid accumulation 0.78 (0.11–5.6) 0.81 2.0 (0.19–20) 0.58
Mucosal bleed 0.42 (0.21–0.84) 0.01 0.44 (0.21–0.92) 0.03
Laboratory parameters at inclusion c
Hematocrit 0.97 (0.95–1.0) 0.06 −1.3 (−2.8–0.33) b 0.12
Hematocrit > 45% 0.54 (0.35–0.82) 0.004 0.49 (0.31–0.78) b 0.003
Platelets 1.0 (1.0–1.0) 0.73 4.1 (−9.8–18) 0.58
Platelets < 100 × 109/L 1.9 (1.1–3.3) 0.02 1.8 (1.0–3.3) 0.05
aAdjusted for age, malaria coinfection, secondary dengue and duration of symptoms at inclusion
bAfter adjustment for hemoglobin result: hematocrit > 45%: 0.48 (0.30–0.76) p = 0.002; hematocrit value: − 1.2 (− 2.7–0.39) p = 0.14
cBlood count values missing in 18 patients









N = 20 N = 408 Unadjusted OR or coefficient
(95% CI)
Adjusted OR or coefficient
(95% CI)
Age, years 36 (27–50) 35 (27–45) 1.0 (0.99–1.05) 0.21 0.98 (0.94–1.0) 0.41
Male sex 10 (50) 217 (53) 0.88 (0.36–2.2) 0.78
Low socioeconomic status 5 (25) 173 (42) 0.45 (0.16–1.3) 0.13
Black race 6 (30) 234 (57) 0.32 (0.12–0.85) 0.02 0.26 (0.09–0.77) 0.02
Private clinic 14 (70) 229 (56) 1.8 (0.69–4.8) 0.22
Malaria coinfection 0 (0) 15 (3.7)
Pregnancy 0 (0) 8 (2.0)
History of diabetes 3 (15) 3 (0.74) 24 (4.5–127) < 0.001 43 (5.2–361) < 0.001
Secondary dengue 3 (15) 554 (13.2) 1.2 (0.33–4.1) 0.82 1.5 (0.40–5.4) 0.56
Warning signs 9 (45) 120 (29) 2.0 (0.79–4.9) 0.14
Abdominal pain 4 (20) 62 (15) 1.4 (0.45–4.3) 0.56
Persistent vomiting 4 (20) 36 (8.8) 2.6 (0.82–8.1) 0.1
Clinical fluid accumulation 1 (5) 3 (0.74) 7.1 (0.71–71.5) 0.1
Mucosal bleed 5 (25) 33 (8) 3.8)1.3–11) 0.02
Laboratory parameters a
Hematocrit, % 43 (41–46) 42 (38–46) 1.0 (0.95–1.1) 0.69
Hematocrit > 45% 7 (35) 113 (28) 1.4 (0.55–3.61) 0.48
Platelets, ×109/L 146 (103–186) 150 (116–189) 1.0 (0.99–1.0) 0.71
Platelets < 100 × 109/L 4 (20) 66 (16) 1.3 (0.42–4.0) 0.65
Leukocytes, ×109/L 9 (45) 134 (33) 0.99 (0.87–1.1) 0.83
Leukocytes < 3.5 × 109/L 9 (45) 134 (33) 1.7 (0.68–4.13) 0.27
aBlood count values missing in 18 patients
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mostly non-black (76%) while patients included in the
public clinics were all black. However, a different ap-
preciation of the warning signs and dengue severity
criteria is unlikely as both study teams were trained
to detect severe signs such as mucosal bleed and used
the same case report form. Blood pressure was mea-
sured with the same device and hematocrit value is
not clinician-dependent. Furthermore, when compar-
ing black patients included in the different setting,
there was no difference in the prevalence of mucosal
bleeding and disease severity.
Black and non-black patients lived in different areas of
the city: most non-black patients living in a privileged
part of the city while most black patients living in poor
and overcrowded wards. However, they were all infected
by the same dengue virus strain. This outbreak was not
caused by an endemic virus strain that had been circu-
lating in Africa before, but was probably imported from
Asia to Tanzania [4, 5]. Black patients were mostly na-
tive of Tanzania while non-black patients were mostly
expatriate coming from different parts of the world and
thus with different environmental exposures in the past.
Therefore, the rate of previous infection by another den-
gue virus serotype might have been different between
black and non-black patients and explain a different
dengue severity as secondary dengue infection by an-
other virus serotype is a risk factor for severe disease via
antibody-dependent infection enhancement while sec-
ondary infection by the same serotype induces protec-
tion [2]. However, the proportion of patients with
secondary dengue was not different between patients of
black and non-black race. Furthermore, we do not ex-
pect protection in the native black population as only
dengue serotype 3 has been described in the past in
Tanzania [6, 27]. Exposure or previous vaccination to
other flavivirus might have conferred cross-protection
against dengue virus. Indeed, black patients native of
Tanzania might have been exposed to yellow fever, West
Nile or other unrecognized flaviviruses in the past or
been vaccinated against yellow fever while Asian patients
might have been exposed to or vaccinated against Japa-
nese encephalitis. All flaviviruses are antigenically related
and serological cross-reactions between flaviviruses are
frequent suggesting that past exposure to a flavivirus
might facilitate a secondary booster enhancement effect
or cross-protection upon exposure to a different but re-
lated virus. In a sero-epidemiologic study, previous ex-
posure to dengue was associated to a reduced severity of
yellow fever among military personnel detached in the
Ecuadorian Amazonia [28]. A study performed in mice
showed a protective effect against dengue viruses in-
duced by the Japanese encephalitis vaccines [29]. Cross-
protection between the Japanese encephalitis virus and
dengue virus was also detected in humans vaccinated with
the Japanese encephalitis vaccine [29]. There has not been
any infection with yellow fever in Tanzania for more than
20 years and yellow fever vaccine is not part of the vaccin-
ation program in Tanzania. But, most expatriates are vac-
cinated against yellow fever as recommended for travelers
visiting Tanzania. However, there is no evidence that pre-
vious yellow fever vaccination has an impact on dengue
severity.
Our study has several strengths. Patients were pro-
spectively included during a dengue outbreak and were
well characterized. Virus genotyping data allowed ruling
out virus characteristics as a factor leading to a differ-
ence in disease severity between racial groups. Our study
has some limitations. First, in this African setting, race
cannot be disentangled from previous exposure to differ-
ent dengue virus serotypes or other endemic flaviruses
as non-black patients were mostly expatriate. Another
limitation is the inclusion of patients by two different
study team leading in a potential different appreciation
of the clinical signs and symptoms of the patients. Third,
blood count analysis was only done at inclusion and we
could not analyze the rise of hematocrit in the course of
the disease.
Conclusions
In conclusion, this study addressing the relation be-
tween race and dengue severity in an African country
showed that patients of black race had a lower inci-
dence of severe dengue. This finding suggests the
presence of protective genetic host factors among
people of African ancestry or environment factors,
such as absence of past exposure to other dengue
virus serotypes (although the prevalence of secondary
dengue in our study was the same) or on the con-
trary previous exposure to endemic flaviviruses con-
ferring cross-protection against severe dengue. The
milder clinical presentation of dengue described in
our study might partly explain why dengue outbreaks
are under-reported in Africa and often mistaken for
malaria. These findings highlight the need to intro-
duce point-of-care tests, beside the one for malaria,
to detect outbreaks in a timely manner and, when an
outbreak is ongoing, to orientate the diagnosis in fe-
brile patients.
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